Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer, as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is based in Boston, Massachusetts.

Aura Biosciences Inc.

Aura Biosciences Inc ( ($AURA) ) just unveiled an update. On July 3, 2026, Aura Biosciences expanded its board from six to seven members and unanim...

Aura Biosciences strengthens board with new independent director

An announcement from Aura Energy ( ($AU:AEE) ) is now available. Aura Energy Limited has notified investors that Sprott Inc., Sprott Asset Manageme...

Aura Energy Flags Exit of Sprott as Substantial Shareholder

Aura Energy ( ($AU:AEE) ) has provided an update. Aura Energy has disclosed a change in director Philip Mitchell’s interests in the company’s secur...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	AURA	$6.99	+1.45%	408.71K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	AURA	$6.99	+1.5%	408.71K
3
4
5
6

AURA

AURA

Get Aura Biosciences Inc. Data in Excel

Get Aura Biosciences Inc. Data in Excel